Disclaimer

For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the  website.

Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.

This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.

Decline
Ranger banner image

Effortless Deliverability. Exceptional Outcomes.

Ranger Drug-Coated Balloon

Ranger™️drug-coated balloon consistently delivers exceptional outcomes with effortless deliverability

Ranger™ consistently delivers exceptional outcomes with effortless deliverability

Restenosis poses a significant, prevalent challenge in superior femoral artery (SFA) management. Boston Scientific is dedicated to overcoming peripheral arterial disease (PAD) challenges with bold innovation using next-generation drug-eluting technology. Boston Scientific is the first company to voluntarily evaluate our drug-coated balloon against another drug-coated balloon (DCB) in a level-1 randomised controlled trial for comparative effectiveness.

Icon representing positive result

Consistently high 12-month primary patency demonstrated across multiple randomised controlled trials (RCT)1,2

Icon representing trial outcomes

Similar outcomes observed with low dose Ranger Drug-Coated Balloon (DCB) compared to higher dose IN.PACT2 DCB

Icon representing reduction

Significantly lower 12-month clinically driven target lesion revascularisation (CD-TLR) rate with Ranger versus uncoated percutaneous transluminal angioplasty (PTA)1

RANGER II clinical trial
COMPARE clinical trial

Ranger demonstrated consistently high primary patency versus uncoated PTA (RANGER II) and IN.PACT (COMPARE) at 12 months¹⁻²

Ranger patency versus PTA and IN.PACT
RANGER II clinical trial
COMPARE clinical trial

Ranger demonstrated similar primary patency to IN.PACT™ DCB, using around half the paclitaxel dose at 12 months²

Ranger low-dose patency versus IN.PACT

Ranger demonstrated a significantly lower 12-month CD-TLR rate versus uncoated PTA, resulting in a 67% relative reduction in repeat procedures¹

Ranger CD-TLR versus uncoated PTA
Icon representing download resources

Receive downloads for clinical data sheets and additional resources for our Drug-Eluting Technologies.

Explore resources
Icon representing get updates

Stay up to date with the latest DET news and events in your area.
 

Register

References

1. Sachar R et al. RANGER II SFA Investigators. 1-year results from the RANGER II SFA randomized trial of the Ranger drug-coated balloon. JACC Cardiovasc Interv. 2021;10:1123–1133.

2. Steiner S, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J. 2020;41:2541–2552.

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.